PMID- 28441320
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2076-2607 (Print)
IS  - 2076-2607 (Electronic)
IS  - 2076-2607 (Linking)
VI  - 5
IP  - 2
DP  - 2017 Apr 25
TI  - Hyperbaric Oxygen Therapy is Ineffective as an Adjuvant to Daptomycin with 
      Rifampicin Treatment in a Murine Model of Staphylococcus aureus in 
      Implant-Associated Osteomyelitis.
LID - 10.3390/microorganisms5020021 [doi]
LID - 21
AB  - Implant-associated infections caused by bacterial biofilms are difficult to 
      treat. Surgical intervention is often necessary to cure the patient, as the 
      antibiotic recalcitrance of biofilms renders them untreatable with conventional 
      antibiotics. Intermittent hyperbaric oxygen treatment (HBOT) has been proposed as 
      an adjuvant to conventional antibiotic treatment and it has been speculated that 
      combining HBOT with antibiotics could improve treatment outcomes for biofilm 
      infections. In this study we addressed whether HBOT could improve treatment 
      outcomes of daptomycin and rifampicin combination therapy. The effect of HBOT on 
      the treatment outcomes of daptomycin and rifampicin against implant-associated 
      osteomyelitis was quantified in a murine model. In total, 80 mice were randomized 
      into two groups receiving antibiotics, either alone or in combination with daily 
      intermittent HBOT (304 kPa for 60 min) following injection of antibiotics. 
      Treatment was initiated 11 days after animals were infected with Staphylococcus 
      aureus and treatment duration was 14 days. We found that HBOT did not improve the 
      cure rate and did not reduce the bacterial load on the implant surface or in the 
      surrounding tissue. Cure rates of daptomycin + rifampicin were 40% in infected 
      tibias and 75% for implants while cure rates for HBOT-daptomycin + rifampicin 
      were 50% and 85%, respectively, which were not significantly higher (Fisher's 
      exact test). While it is encouraging that the combination of daptomycin and 
      rifampicin is very effective, our study demonstrates that this efficacy cannot be 
      improved by adjuvant HBOT.
FAU - Jorgensen, Nis Pedersen
AU  - Jorgensen NP
AD  - Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus, 
      Denmark. nisjoe@rm.dk.
AD  - Department of Clinical Microbiology, Aarhus University Hospital, 8200 Aarhus, 
      Denmark. nisjoe@rm.dk.
FAU - Hansen, Kasper
AU  - Hansen K
AD  - Comparative Medicine Lab, Department of Clinical Medicine, Aarhus University 
      Hospital, 8200 Aarhus, Denmark. kasperhansen@bios.au.dk.
FAU - Andreasen, Caroline Marie
AU  - Andreasen CM
AD  - Department of Rheumatology, Aarhus University Hospital, 8200 Aarhus, Denmark. 
      c.m.andreasen@clin.au.dk.
FAU - Pedersen, Michael
AU  - Pedersen M
AD  - Comparative Medicine Lab, Department of Clinical Medicine, Aarhus University 
      Hospital, 8200 Aarhus, Denmark. michael@clin.au.dk.
FAU - Fuursted, Kurt
AU  - Fuursted K
AD  - Microbiology and Infection Control, Statens Serum Institut, 2300 Copenhagen, 
      Denmark. kfu@ssi.dk.
FAU - Meyer, Rikke L
AU  - Meyer RL
AD  - Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus, 
      Denmark. rikke.meyer@inano.au.dk.
AD  - Department of Bioscience, Aarhus University, 8000 Aarhus, Denmark. 
      rikke.meyer@inano.au.dk.
FAU - Petersen, Eskild
AU  - Petersen E
AD  - Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus, 
      Denmark. eskild.petersen@clin.au.dk.
AD  - Department of Clinical Microbiology, Aarhus University Hospital, 8200 Aarhus, 
      Denmark. eskild.petersen@clin.au.dk.
LA  - eng
PT  - Journal Article
DEP - 20170425
PL  - Switzerland
TA  - Microorganisms
JT  - Microorganisms
JID - 101625893
PMC - PMC5488092
OTO - NOTNLM
OT  - Implant-associated osteomyelitis
OT  - Staphylococcus aureus
OT  - biofilm
OT  - bone turnover
OT  - hyperbaric oxygen therapy
OT  - inflammation
COIS- The founding sponsors had no role in the design of the study; in the collection, 
      analyses, or interpretation of data; in the writing of the manuscript, and in the 
      decision to publish the results.
EDAT- 2017/04/26 06:00
MHDA- 2017/04/26 06:01
PMCR- 2017/04/25
CRDT- 2017/04/26 06:00
PHST- 2017/03/19 00:00 [received]
PHST- 2017/04/18 00:00 [revised]
PHST- 2017/04/19 00:00 [accepted]
PHST- 2017/04/26 06:00 [entrez]
PHST- 2017/04/26 06:00 [pubmed]
PHST- 2017/04/26 06:01 [medline]
PHST- 2017/04/25 00:00 [pmc-release]
AID - microorganisms5020021 [pii]
AID - microorganisms-05-00021 [pii]
AID - 10.3390/microorganisms5020021 [doi]
PST - epublish
SO  - Microorganisms. 2017 Apr 25;5(2):21. doi: 10.3390/microorganisms5020021.